A large global study provides new evidence supporting the use of blood biomarkers in an Alzheimer's clinical trial to screen for elevated brain amyloid levels among potential participants who are cognitively unimpaired. The findings, published in JAMA Neurology, show that the relationship between blood biomarker levels and brain amyloid was largely similar across racial groups.